What is ALKS stock price today?

ALKS (Alkermes Plc) stock is trading at $33.22 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is ALKS stock going up or down today?

ALKS stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy ALKS stock now?

The decision to buy ALKS depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is ALKS a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for ALKS based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is ALKS stock overvalued or undervalued?

ALKS currently trades at a P/E ratio of 23.69 relative to earnings. Our DCF calculator provides intrinsic value estimates to help determine if ALKS is fairly priced.

What is ALKS's P/E ratio?

ALKS has a price-to-earnings (P/E) ratio of 23.69, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is ALKS's market cap?

ALKS (Alkermes Plc) has a market capitalization of $5.64 billion, making it a small-cap stock.

What is ALKS's price to book ratio?

ALKS trades at a price-to-book (P/B) ratio of 3.08, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does ALKS pay dividends?

ALKS does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is ALKS's dividend yield?

ALKS does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is ALKS stock a good long-term investment?

ALKS's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is ALKS's revenue growth rate?

ALKS has shown revenue growth of -0.1% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, ALKS is profitable with a profit margin of 0.2%. This indicates the company generates 0.2 cents of profit for every dollar of revenue.

What are the risks of investing in ALKS?

Key risks for ALKS include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does ALKS compare to its competitors?

Compare ALKS to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize ALKS's performance and positioning.

What is ALKS's stock price target for 2026?

Our AI model provides price targets for ALKS based on fundamental analysis: Bull case $43.19 (+30%), Base case $38.20 (+15%), Bear case $29.90 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about ALKS?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for ALKS. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is ALKS's next earnings report?

ALKS reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

ALKS - Alkermes Plc

NYSE * Health Care * Pharmaceuticals

$33.22

$-0.65 (-1.92%)

About Alkermes Plc

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

ALKS Key Statistics

Market Cap

$5.64B

P/E Ratio

23.69

P/B Ratio

3.08

EPS

$1.43

Revenue Growth

-0.1%

Profit Margin

0.2%

Employees

2,050

How ALKS Compares to Peers

ALKS has the lowest P/E ratio in Pharmaceuticals, suggesting it may be the most undervalued

ALKS has the highest profit margins in Pharmaceuticals

ALKS is the smallest among peers, which may offer higher growth potential

P/E Rank

of 2

Margin Rank

of 2

Growth Rank

of 2

Size Rank

of 2

Company	Market Cap	P/E	Growth	Margin	Compare
ALKS(This stock)	$5.64B	23.7	-0%	0.2%	-
AMZNAmazon Com	$2.68T	34.7	0%	0.1%	vs AMZN

Alkermes Plc Company Information

Headquarters: Ireland
Website: www.alkermes.com
Sector: Health Care
Industry: Pharmaceuticals

ALKS - Alkermes Plc

About Alkermes Plc

ALKS Key Statistics

How ALKS Compares to Peers

Alkermes Plc Company Information

ALKS Lician Score

ALKS Financial Snowflake

Upcoming Events for ALKS